Pasithea Therapeutics Corp. (KTTA)
0.5804
0.00 (0.00%)
USD |
NASDAQ |
Sep 04, 11:30
Pasithea Therapeutics Debt to Equity Ratio : 0.00 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.00 |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 0.00 |
| September 30, 2025 | 0.0032 |
| June 30, 2025 | 0.0102 |
| March 31, 2025 | 0.0207 |
| December 31, 2024 | 0.00 |
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.0017 |
| December 31, 2023 | 0.0035 |
| Date | Value |
|---|---|
| September 30, 2023 | 0.0136 |
| June 30, 2023 | 0.0157 |
| March 31, 2023 | 0.0186 |
| December 31, 2022 | 0.0119 |
| September 30, 2022 | 0.021 |
| June 30, 2022 | 0.0089 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
| Vericel Corp. | 0.2556 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 51.71M |
| Total Liabilities (Quarterly) | 1.870M |
| Shareholders Equity (Quarterly) | 49.84M |
| Current Ratio | 26.25 |
| Net Debt Paydown Yield | 0.31% |